Repression of cyclin D1 as a target for germ cell tumors

Sarah J. Freemantle, Angelina V. Vaseva, Katherine E. Ewings, Thomas Bee, Katey A. Krizan, Mark Kelley, Eyas M. Hattab, Vincent A. Memoli, Candice C. Black, Michael J. Spinella, Ethan Dmitrovsky

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Metastatic germ cell tumors (GCT) are curable, however GCTs refractory to cisplatin-based chemotherapy have a poor prognosis. This study explores D-type cyclins as molecular targets in GCTs because all-trans-retinoic acid (RA)-mediated differentiation of the human embryonal carcinoma (EC) cell line NT2/D1 is associated with G1 cell cycle arrest and proteasomal degradation of cyclin D1. RA effects on D-type cyclins are compared in human EC cells that are RA sensitive or dually RA and cisplatin resistant (NT2/D1-R1) and in clinical GCTs that have both EC and mature teratoma components. Notably, GCT differentiation was associated with reduced cyclin D1 but increased cyclin D3 expression. RA was shown here to repress cyclin D1 through a transcriptional mechanism in addition to causing its degradation. The siRNA-mediated repression of individual cyclin D species resulted in growth inhibition in both RA sensitive and resistant EC cells. Only repression of cyclin D1 occurred in vitro and when clinical GCTs mature, implicating cyclin D1 as a molecular therapeutic target. To confirm this, the EGFR-tyrosine kinase inhibitor, Erlotinib, was used to repress cyclin D1. This inhibited proliferation in RA and cisplatin sensitive and resistant EC cells. Taken together, these findings implicate cyclin D1 targeting agents for the treatment of GCTs.

Original languageEnglish
Pages (from-to)333-340
Number of pages8
JournalInternational Journal of Oncology
Volume30
Issue number2
StatePublished - Feb 2007

Fingerprint

Germ Cell and Embryonal Neoplasms
Cyclin D1
Tretinoin
Embryonal Carcinoma Stem Cells
Cyclin D
Cisplatin
Cyclin D3
Embryonal Carcinoma
G1 Phase Cell Cycle Checkpoints
Teratoma
Protein-Tyrosine Kinases
Small Interfering RNA
Cell Differentiation
Drug Therapy
Cell Line
Therapeutics
Growth

Keywords

  • Cyclin D1
  • Cyclin D3
  • Germ cell tumor differentiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Freemantle, S. J., Vaseva, A. V., Ewings, K. E., Bee, T., Krizan, K. A., Kelley, M., ... Dmitrovsky, E. (2007). Repression of cyclin D1 as a target for germ cell tumors. International Journal of Oncology, 30(2), 333-340.

Repression of cyclin D1 as a target for germ cell tumors. / Freemantle, Sarah J.; Vaseva, Angelina V.; Ewings, Katherine E.; Bee, Thomas; Krizan, Katey A.; Kelley, Mark; Hattab, Eyas M.; Memoli, Vincent A.; Black, Candice C.; Spinella, Michael J.; Dmitrovsky, Ethan.

In: International Journal of Oncology, Vol. 30, No. 2, 02.2007, p. 333-340.

Research output: Contribution to journalArticle

Freemantle, SJ, Vaseva, AV, Ewings, KE, Bee, T, Krizan, KA, Kelley, M, Hattab, EM, Memoli, VA, Black, CC, Spinella, MJ & Dmitrovsky, E 2007, 'Repression of cyclin D1 as a target for germ cell tumors', International Journal of Oncology, vol. 30, no. 2, pp. 333-340.
Freemantle SJ, Vaseva AV, Ewings KE, Bee T, Krizan KA, Kelley M et al. Repression of cyclin D1 as a target for germ cell tumors. International Journal of Oncology. 2007 Feb;30(2):333-340.
Freemantle, Sarah J. ; Vaseva, Angelina V. ; Ewings, Katherine E. ; Bee, Thomas ; Krizan, Katey A. ; Kelley, Mark ; Hattab, Eyas M. ; Memoli, Vincent A. ; Black, Candice C. ; Spinella, Michael J. ; Dmitrovsky, Ethan. / Repression of cyclin D1 as a target for germ cell tumors. In: International Journal of Oncology. 2007 ; Vol. 30, No. 2. pp. 333-340.
@article{6d6232ca951e4200aebe05273b6db41c,
title = "Repression of cyclin D1 as a target for germ cell tumors",
abstract = "Metastatic germ cell tumors (GCT) are curable, however GCTs refractory to cisplatin-based chemotherapy have a poor prognosis. This study explores D-type cyclins as molecular targets in GCTs because all-trans-retinoic acid (RA)-mediated differentiation of the human embryonal carcinoma (EC) cell line NT2/D1 is associated with G1 cell cycle arrest and proteasomal degradation of cyclin D1. RA effects on D-type cyclins are compared in human EC cells that are RA sensitive or dually RA and cisplatin resistant (NT2/D1-R1) and in clinical GCTs that have both EC and mature teratoma components. Notably, GCT differentiation was associated with reduced cyclin D1 but increased cyclin D3 expression. RA was shown here to repress cyclin D1 through a transcriptional mechanism in addition to causing its degradation. The siRNA-mediated repression of individual cyclin D species resulted in growth inhibition in both RA sensitive and resistant EC cells. Only repression of cyclin D1 occurred in vitro and when clinical GCTs mature, implicating cyclin D1 as a molecular therapeutic target. To confirm this, the EGFR-tyrosine kinase inhibitor, Erlotinib, was used to repress cyclin D1. This inhibited proliferation in RA and cisplatin sensitive and resistant EC cells. Taken together, these findings implicate cyclin D1 targeting agents for the treatment of GCTs.",
keywords = "Cyclin D1, Cyclin D3, Germ cell tumor differentiation",
author = "Freemantle, {Sarah J.} and Vaseva, {Angelina V.} and Ewings, {Katherine E.} and Thomas Bee and Krizan, {Katey A.} and Mark Kelley and Hattab, {Eyas M.} and Memoli, {Vincent A.} and Black, {Candice C.} and Spinella, {Michael J.} and Ethan Dmitrovsky",
year = "2007",
month = "2",
language = "English",
volume = "30",
pages = "333--340",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Repression of cyclin D1 as a target for germ cell tumors

AU - Freemantle, Sarah J.

AU - Vaseva, Angelina V.

AU - Ewings, Katherine E.

AU - Bee, Thomas

AU - Krizan, Katey A.

AU - Kelley, Mark

AU - Hattab, Eyas M.

AU - Memoli, Vincent A.

AU - Black, Candice C.

AU - Spinella, Michael J.

AU - Dmitrovsky, Ethan

PY - 2007/2

Y1 - 2007/2

N2 - Metastatic germ cell tumors (GCT) are curable, however GCTs refractory to cisplatin-based chemotherapy have a poor prognosis. This study explores D-type cyclins as molecular targets in GCTs because all-trans-retinoic acid (RA)-mediated differentiation of the human embryonal carcinoma (EC) cell line NT2/D1 is associated with G1 cell cycle arrest and proteasomal degradation of cyclin D1. RA effects on D-type cyclins are compared in human EC cells that are RA sensitive or dually RA and cisplatin resistant (NT2/D1-R1) and in clinical GCTs that have both EC and mature teratoma components. Notably, GCT differentiation was associated with reduced cyclin D1 but increased cyclin D3 expression. RA was shown here to repress cyclin D1 through a transcriptional mechanism in addition to causing its degradation. The siRNA-mediated repression of individual cyclin D species resulted in growth inhibition in both RA sensitive and resistant EC cells. Only repression of cyclin D1 occurred in vitro and when clinical GCTs mature, implicating cyclin D1 as a molecular therapeutic target. To confirm this, the EGFR-tyrosine kinase inhibitor, Erlotinib, was used to repress cyclin D1. This inhibited proliferation in RA and cisplatin sensitive and resistant EC cells. Taken together, these findings implicate cyclin D1 targeting agents for the treatment of GCTs.

AB - Metastatic germ cell tumors (GCT) are curable, however GCTs refractory to cisplatin-based chemotherapy have a poor prognosis. This study explores D-type cyclins as molecular targets in GCTs because all-trans-retinoic acid (RA)-mediated differentiation of the human embryonal carcinoma (EC) cell line NT2/D1 is associated with G1 cell cycle arrest and proteasomal degradation of cyclin D1. RA effects on D-type cyclins are compared in human EC cells that are RA sensitive or dually RA and cisplatin resistant (NT2/D1-R1) and in clinical GCTs that have both EC and mature teratoma components. Notably, GCT differentiation was associated with reduced cyclin D1 but increased cyclin D3 expression. RA was shown here to repress cyclin D1 through a transcriptional mechanism in addition to causing its degradation. The siRNA-mediated repression of individual cyclin D species resulted in growth inhibition in both RA sensitive and resistant EC cells. Only repression of cyclin D1 occurred in vitro and when clinical GCTs mature, implicating cyclin D1 as a molecular therapeutic target. To confirm this, the EGFR-tyrosine kinase inhibitor, Erlotinib, was used to repress cyclin D1. This inhibited proliferation in RA and cisplatin sensitive and resistant EC cells. Taken together, these findings implicate cyclin D1 targeting agents for the treatment of GCTs.

KW - Cyclin D1

KW - Cyclin D3

KW - Germ cell tumor differentiation

UR - http://www.scopus.com/inward/record.url?scp=34047255082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047255082&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 333

EP - 340

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -